全文获取类型
收费全文 | 979篇 |
免费 | 44篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 22篇 |
妇产科学 | 2篇 |
基础医学 | 310篇 |
口腔科学 | 22篇 |
临床医学 | 87篇 |
内科学 | 147篇 |
皮肤病学 | 5篇 |
神经病学 | 65篇 |
特种医学 | 72篇 |
外科学 | 121篇 |
综合类 | 12篇 |
预防医学 | 25篇 |
眼科学 | 27篇 |
药学 | 38篇 |
肿瘤学 | 60篇 |
出版年
2022年 | 12篇 |
2021年 | 19篇 |
2020年 | 17篇 |
2019年 | 18篇 |
2018年 | 17篇 |
2017年 | 13篇 |
2016年 | 9篇 |
2015年 | 21篇 |
2014年 | 20篇 |
2013年 | 20篇 |
2012年 | 33篇 |
2011年 | 38篇 |
2010年 | 18篇 |
2009年 | 24篇 |
2008年 | 30篇 |
2007年 | 29篇 |
2006年 | 33篇 |
2005年 | 33篇 |
2004年 | 33篇 |
2003年 | 34篇 |
2002年 | 28篇 |
2001年 | 17篇 |
2000年 | 26篇 |
1999年 | 21篇 |
1997年 | 5篇 |
1996年 | 7篇 |
1995年 | 8篇 |
1993年 | 5篇 |
1992年 | 12篇 |
1991年 | 18篇 |
1990年 | 18篇 |
1989年 | 16篇 |
1988年 | 13篇 |
1987年 | 17篇 |
1986年 | 6篇 |
1985年 | 11篇 |
1984年 | 10篇 |
1983年 | 5篇 |
1979年 | 7篇 |
1978年 | 5篇 |
1943年 | 15篇 |
1942年 | 19篇 |
1941年 | 23篇 |
1940年 | 10篇 |
1939年 | 31篇 |
1938年 | 36篇 |
1937年 | 32篇 |
1936年 | 37篇 |
1935年 | 36篇 |
1934年 | 6篇 |
排序方式: 共有1026条查询结果,搜索用时 109 毫秒
11.
Unilateral external fixation requires an anatomically sound implantation of screws into the upper extremity. Detailed knowledge about the anatomical situation in the areas of pin implantation is of great importance. This paper focuses on relevant anatomical landmarks when implanting screws for external fixation in the humerus, the elbow, the forearm and the hand by studying anatomical specimen. 相似文献
12.
The minimally-invasive treatment of metacarpal and phalangeal fractures with a low profile external fixator is described. In most sites fixator pins are inserted percutaneously and closed reduction of the fracture is performed. Due to the special design bridging of adjacent joints in shaft, distal or proximal fractures is not necessary unless the fracture is intraarticular. The results of treatment are described. Advantages and disadvantages of a small external fixator in relation to conservative management and open reduction and internal fixation are discussed. 相似文献
13.
14.
Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial 总被引:1,自引:0,他引:1
Silverman MH Strand V Markovits D Nahir M Reitblat T Molad Y Rosner I Rozenbaum M Mader R Adawi M Caspi D Tishler M Langevitz P Rubinow A Friedman J Green L Tanay A Ochaion A Cohen S Kerns WD Cohn I Fishman-Furman S Farbstein M Yehuda SB Fishman P 《The Journal of rheumatology》2008,35(1):41-48
OBJECTIVE: Adenosine exerts antiinflammatory effects via activation of the A3 adenosine receptor (A3AR), a Gi protein-associated cell-surface receptor, overexpressed in synovial tissue and peripheral blood mononuclear cells (PBMC) in patients with active rheumatoid arthritis (RA). CF101 is a highly specific orally bioavailable A3AR agonist. METHODS: This was a multicenter study, blinded to dose, designed to assess the clinical activity and safety of CF101 in active RA. Seventy-four patients were randomized to receive 0.1, 1.0, or 4.0 mg CF101 bid for 12 weeks. The primary efficacy endpoint was American College of Rheumatology 20% response (ACR20) at Week 12. A3AR expression levels were analyzed in PBMC from 18 patients. RESULTS:. Maximal responses were observed with 1.0 mg bid, lower at 0.1 and 4.0 mg bid. At 12 weeks, 55.6%, 33.3%, and 11.5% of the patients receiving 1.0 mg CF101 achieved ACR20%, 50%, and 70% responses, respectively. CF101 was generally well tolerated, with mild headache (4.1%), nausea (2.7%), and rash (2.7%) being the most common treatment-related adverse events. Statistically significant correlations between A3AR overexpression at baseline and ACR50 and ACR70 responses were observed. CONCLUSION: CF101 administered bid for 12 weeks resulted in improvement in signs and symptoms of RA that did not achieve statistical significance, and was safe and well tolerated. The expression level of A3AR was directly correlated with patient responses to CF101, suggesting its utilization as a biomarker for the pharmacodynamic and therapeutic effects of this novel agent. These findings require confirmation in a double-blind randomized placebo-controlled trial, currently under way. 相似文献
15.
Pamela Harmon Eduard Cojocari Catherine Lynn Mader Charlene Galloway Megan Buchholz Brenda Lewis Susan Sinclair 《Transfusion and apheresis science》2018,57(3):437-444
A group of Canadian apheresis nurses developed best practice for in the management of thrombotic thrombocytopenic purpura (TTP). The recommendations address issues related to infusion protocols, preventing and managing adverse events, comprehensive patient assessments, treatment procedures, as well as pre- and post- treatment care. The Canadian group encourages institutes to include nurses on committees that examine recommendations for TTP management. 相似文献
16.
G. G. Steger C. Dittrich O. Schlappack R. Mader C. Herold W. P. Brade A. Keller K. Moser 《Journal of cancer research and clinical oncology》1988,114(6):602-604
Summary Twenty-six cycles of high-dose ifosfamide+mesna (HD-IFO+M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO+M over 24 h appeared to be the best tolerated. On partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks. 相似文献
17.
The aim of this study was to evaluate the prevalence and the performance of lupus anticoagulant (LA) tests in a heterogeneous
group of patients and to investigate the sociodemographic characteristics, patterns of referral, clinical manifestations and
outcomes among these patients. The medical charts of 725 patients referred to a central coagulation laboratory during a 12-month
period for LA were reviewed. The data collected included demographic characteristics, the specialty of the referring physicians,
the clinical indications for ordering the test, and the influence of the test results on the diagnosis and the treatment approach.
Special attention was paid to identifying clinical manifestations known to be associated with antiphospholipid antibodies
(APLA). A positive test was defined by abnormal results obtained by at least two techniques from the reagents used and confirmed
by a platelet-neutralising procedure. χ2 and t-tests were used for independent samples. Fifty-six patients (7.7%) were found to have LA. Rheumatologists and gynaecologists
emerged as the major contributors to this group. The presence of LA was significantly associated only with systemic lupus
erythematosus and thrombocytopenia. The number of patients treated with antiaggregants or anticoagulants tripled following
the test results. A positive dRVVT test strongly correlated with elevated anticardiolipin antibodies. We concluded that LA
tests are ordered by a variety of physicians but yield better results when ordered by rheumatologists and gynaecologists.
In this heterogeneous cohort, it was most useful in the investigation of thrombocytopenia and suggests a pathogenetic role
in this condition. The dRVVT test correlates most closely with elevated anticardiolipin antibodies.
Received: 10 December 2001 / Accepted: 27 May 2002 相似文献
18.
Polyarteritis nodosa involves necrotising vasculitis of small and medium-sized arteries. Multiple organ systems are involved.
A non-specific and slow course of disease is common. Gastrointestinal involvement is characterised by abdominal pain, nausea
and vomiting. Bowel infarction and perforation, cholecystitis and hepatic infarction are well known complications. However,
bowel infarction as the presenting symptom of the disease is rare. The case of a 20-year-old male with necrosis of the duodenum
heralding polyarteritis nodosa is reported. The patient made a slow recovery after extensive abdominal surgery and a stormy
course. The postoperative management and treatment of polyarteritis nodosa are discussed. A high index of suspicion and prompt
multidisciplinary approach are needed in order to improve survival in these rare but potentially fatal conditions.
Received: 15 May 2001 / Accepted: 5 February 2002 相似文献
19.
Lia Burkhardt Frederic Bachmann Malte Mader Katharina Grupp Till Eichenauer Andreas Becker Meike Adam Markus Graefen Hartwig Huland Stefan Kurtz Stefan Steurer Maria C Tsourlakis Sarah Minner Uwe Michl Thorsten Schlomm Guido Sauter Hüseyin Sirma 《The Journal of pathology》2013,231(1):130-141
Deletion of 3p13 has been reported from about 20% of prostate cancers. The clinical significance of this alteration and the tumour suppressor gene(s) driving the deletion remain to be identified. We have mapped the 3p13 deletion locus using SNP array analysis and performed fluorescence in situ hybridization (FISH) analysis to search for associations between 3p13 deletion, prostate cancer phenotype and patient prognosis in a tissue microarray containing more than 3200 prostate cancers. SNP array analysis of 72 prostate cancers revealed a small deletion at 3p13 in 14 (19%) of the tumours, including the putative tumour suppressors FOXP1, RYBP and SHQ1. FISH analysis using FOXP1‐specific probes revealed deletions in 16.5% and translocations in 1.2% of 1828 interpretable cancers. 3p13 deletions were linked to adverse features of prostate cancer, including advanced stage (p < 0.0001), high Gleason grade (p = 0.0125), and early PSA recurrence (p = 0.0015). In addition, 3p13 deletions were linked to ERG+ cancers and to PTEN deletions (p < 0.0001 each). A subset analysis of ERG+ tumours revealed that 3p13 deletions occurred independently from PTEN deletions (p = 0.3126), identifying tumours with 3p13 deletion as a distinct molecular subset of ERG+ cancers. mRNA expression analysis confirmed that all 3p13 genes were down regulated by the deletion. Ectopic over‐expression of FOXP1, RYBP and SHQ1 resulted in decreased colony‐formation capabilities, corroborating a tumour suppressor function for all three genes. In summary, our data show that deletion of 3p13 defines a distinct and aggressive molecular subset of ERG+ prostate cancers, which is possibly driven by inactivation of multiple tumour suppressors. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. 相似文献
20.